BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32519591)

  • 1. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching treatments in COPD: implications for costs and treatment adherence.
    Braido F; Lavorini F; Blasi F; Baiardini I; Canonica GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice.
    Fens T; van der Pol S; Kocks JWH; Postma MJ; van Boven JFM
    Value Health; 2019 Oct; 22(10):1092-1101. PubMed ID: 31563251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.
    Tavakoli H; Johnson KM; FitzGerald JM; Sin DD; Gershon AS; Kendzerska T; Sadatsafavi M
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2003-2013. PubMed ID: 31564848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend of cost and utilization of COPD medication in Korea.
    Lee J; Lee JH; Kim JA; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
    Roggeri A; Micheletto C; Roggeri DP
    Int J Chron Obstruct Pulmon Dis; 2014; 9():569-76. PubMed ID: 24940053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.
    van der Schans S; Goossens LMA; Boland MRS; Kocks JWH; Postma MJ; van Boven JFM; Rutten-van Mölken MPMH
    Pharmacoeconomics; 2017 Jan; 35(1):43-63. PubMed ID: 27592021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When is dual bronchodilation indicated in COPD?
    Thomas M; Halpin DM; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2291-2305. PubMed ID: 28814857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.